Abstract: The present disclosure provides a recombinant collagen and a recombinant collagen sponge material. The recombinant collagen comprises: (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2; and/or (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2. The recombinant collagen sponge material is obtained by sequential physical cross-linking and chemical cross-linking of the recombinant collagen. The recombinant collagen sponge material according to the present disclosure is capable of hemostasis, wound surface repair, moisture absorption and platelet aggregation, and has high moisture absorption, a significant hemostatic effect and good biocompatibility, assuming great clinical significance in the field of surgery.

Abstract: The present invention provides novel artificial tears containing a recombinant human lysozyme. The novel artificial tears comprise main components and an auxiliary material. The main components are a recombinant human lysozyme and a sodium hyaluronate, wherein the recombinant human lysozyme and the sodium hyaluronate are contained in an amount from 0.075%-0.300% and from 0.10%-0.30%, respectively in the total mass of the novel artificial tears. A drug for external use is prepared by combining the recombinant human lysozyme, the sodium hyaluronate and an excipient for treating light and moderate dry eye syndrome.

Abstract: The present invention provides novel artificial tears containing a recombinant human lysozyme and a recombinant human epidermal growth factor. The novel artificial tears comprise main components and an auxiliary material. The main components are a recombinant human lysozyme, a recombinant human epidermal growth factor, and sodium hyaluronate, wherein the recombinant human lysozyme, the recombinant human epidermal growth factor, and sodium hyaluronate are contained in an amount from 0.075% to 0.300%, from 0.002% to 0.004%, and from 0.10% to 0.30%, respectively in the total mass of the novel artificial tears.

Abstract: A cosmetic composition, comprising osteogenic growth peptide carbon-terminal pentapeptide, and at least one of a carrier, a diluent and an adjuvant. The cosmetic composition can promote the proliferation of fibroblasts and the synthesis of skin collagen, and also has the effects of promoting skin wound healing, and eliminating swelling and inflammation.